Course of Development and Controversy on Andrology Seville 2012

25
NUEVAS ESTRATEGIAS TERAPÉUTICAS. NUEVOS PARADIGMAS. Eduardo García-Cruz Urología y Salud del Hombre Servicio de Urología Hospital Clínic de Barcelona www.reisho.com

description

Update in latest treatments in the field of erectile disfunction.

Transcript of Course of Development and Controversy on Andrology Seville 2012

Page 1: Course of Development and Controversy on Andrology Seville 2012

NUEVAS ESTRATEGIAS TERAPÉUTICAS. NUEVOS PARADIGMAS.

Eduardo García-CruzUrología y Salud del Hombre

Servicio de UrologíaHospital Clínic de Barcelona

www.reisho.com

Page 2: Course of Development and Controversy on Andrology Seville 2012

50%

*Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14:S99–104.

Page 3: Course of Development and Controversy on Andrology Seville 2012

Menos eficacia de la esperada.

Pérdida de interés por el sexo.

Pérdida de espontaneidad.

Problemas de pareja.

Coste.

Page 4: Course of Development and Controversy on Andrology Seville 2012

PASTILLAS

ENERÓTESIS3

Page 5: Course of Development and Controversy on Andrology Seville 2012
Page 6: Course of Development and Controversy on Andrology Seville 2012

1. Nuevas formulaciones iPDE-5

Vardenafil 10mg BDTadalafil 5/24

2. Nuevos iPDE-5

AvanafilUdenafilMirodenafilLodenafilSlX 2101

3. MUSE

4. Self management

Page 7: Course of Development and Controversy on Andrology Seville 2012

Misma eficacia.Igual perfil de seguridad.

Page 8: Course of Development and Controversy on Andrology Seville 2012

Rápido

Precio

Discreto

Ansiedad de ejecución

Page 9: Course of Development and Controversy on Andrology Seville 2012

Eficacia entre 10 y 20mg.

Menos efectos secundarios.

Page 10: Course of Development and Controversy on Andrology Seville 2012

Desvincular el fármaco de la relación sexual.

Más sexo?

No planificación.

Más naturalidad.

PRECIO

Sobretratamiento?

Más sensación subjetiva deenfermedad?

Cumplimiento.

Page 11: Course of Development and Controversy on Andrology Seville 2012

FÁRMACO PAÍS NOMBRECOMERCIAL

T MAX T 1/2 USOS?

AVANAFIL COREA STENDRA 35 min <90 min NITRATOS

UDENAFIL COREA ZYDENA 60 min 10 h USO DIARIO

MIRODENAFIL COREA MVIX 90 min 2,4 h

LODENAFIL BRASIL HELLEVA 70 min 2,4h

SLX-2101 USA - 60 min 8-13 h USO DIARIO

Page 12: Course of Development and Controversy on Andrology Seville 2012
Page 13: Course of Development and Controversy on Andrology Seville 2012

Menos eficaz.

Menos agresivo.

Page 14: Course of Development and Controversy on Andrology Seville 2012

Menos invasivo.

Mejor tolerado

Menos eficaz.

Page 15: Course of Development and Controversy on Andrology Seville 2012
Page 16: Course of Development and Controversy on Andrology Seville 2012

Tratamiento etiológico.

Mejora comorbilidad.

Curativo.

Time-consuming.

Requiere personal entrenado.

Requiere hombres motivados.

Lento.

Caro.

Page 17: Course of Development and Controversy on Andrology Seville 2012
Page 18: Course of Development and Controversy on Andrology Seville 2012
Page 19: Course of Development and Controversy on Andrology Seville 2012

NUEVAS ESTRATEGIAS TERAPÉUTICAS. NUEVOS PARADIGMAS.

Eduardo García-CruzUrología y Salud del Hombre

Servicio de UrologíaHospital Clínic de Barcelona

www.reisho.com

Page 20: Course of Development and Controversy on Andrology Seville 2012
Page 21: Course of Development and Controversy on Andrology Seville 2012
Page 22: Course of Development and Controversy on Andrology Seville 2012
Page 23: Course of Development and Controversy on Andrology Seville 2012
Page 24: Course of Development and Controversy on Andrology Seville 2012
Page 25: Course of Development and Controversy on Andrology Seville 2012